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Aims: Althoughmorphine, at higher doses, induces analgesia, it may also enhance sensitivity to pain at extremely
lowdoses as shown in studies for testing an animal's sensitivity to pain.We used an antisense approach capable of
selectively down-regulating in vivo Gi(G inhibitory protein),Go and Gs members of the Gα sub-family protein
subunits in order to establish if these proteins might be implicated in the effects induced by extremely lowmor-
phine doses on acute thermonociception.
Main methods: Mice pretreated with a morphine hyperalgesic dose (1 μg/kg) were submitted to hot plate test
after pre-treatment with antisense oligodeoxynucleotides (aODNs) targeting Giα, Goα and Gsα regulatory pro-
teins. The association of G-protein (guanine nucleotide-binding regulatory protein) coupled receptors with G
protein was investigated using co-immunoprecipitation procedure.
Key findings: The downregulation of the Giα1–3 and Goα1 proteins reversed the licking latency responses induced
by 1 μg/kgmorphine administration toward the basal valuewhereas downregulation of the Goα2 and Gsα proteins
did not significantly modify the hyperalgesic response.
Significance: These results suggest that G inhibitory proteins play a role in the production of low dose evoked
morphine hyperalgesia in mouse. Immunoprecipitation studies revealed that both μ opioid receptor (μOR) and
α2 adrenoreceptor (α2 AR) are bound to G inhibitory proteins in hyperalgesic response to morphine extremely
low dose. Both μOR and α2 AR appear to be necessary for low morphine dose induced hyperalgesic response
through G inhibitory proteins.© 2011 Elsevier Inc. All rights reserved.Introduction
Hyperalgesic and analgesic actions, aswell as biphasic dose–response
relationships, have been demonstrated in animals and humans following
administration of opioids (Kayan et al., 1971; Jacquet and Lajtha, 1973;
Levine et al., 1978; Woolf, 1981; Gracely et al., 1983). Different
authors demonstrated that extremely low doses of morphine (less than
1 μg/kg) can elicit acute thermal hyperalgesia in animal model of pain
as tail flick and Freund's adjuvant-induced arthritic rats (Kayser et al.,
1987). The intraplantar application of micromolar doses of morphine
has been proved to induce a flexor response in mice (Ono et al., 2002).
Depending on the type of cell used and dose applied, opioids can induce
hyperpolarization or depolarization and either inhibit or stimulateto di Neuroscienze-Università
77 234151.
rights reserved.neuronal cells. On the basis of electrophysiological studies, it was sug-
gested that either stimulatory or inhibitory influence onneurones by opi-
oid agonists depends on the dose applied (North and Uchimura, 1989;
Crain and Shen, 1990; Smart and Lambert, 1996; Keren et al., 1999).
Studies in primary dorsal root ganglion cultures showed that neuronal
stimulation occurred at nanomolar concentrations of opioidswhereas in-
hibition occurred at micromolar concentrations. This led to the proposal
that there might be separate stimulatory and inhibitory effects linked to
different effector systems indicating that opioid receptor coupling switch
fromG inhibitory (Gi) protein toG stimulatory (Gs) protein under certain
conditions (Crain and Shen, 1998). Different G protein (guanine
nucleotide-binding regulatory protein) classes activated by morphine
in the production of spinal and supraspinal antinociception have been
identified: Giα2, Goα and Gsα proteins appeared to have a main role in
supraspinal μOR opioid analgesia tested in animal model of thermal
pain whereas Giα2 was determinant in mediating spinal analgesia
(Standifer et al., 1996; Garzon et al., 2000). Therefore we used an
antisense approach capable of selectively down-regulate in vivo Gs and
Gi/Go members of the Gα sub-family protein subunits in order to estab-
lish if also these proteins might be implicated in the effects induced by
morphine acute administration at extremely low doses.
Table 1
Sequences of antisense, mismatch and degenerate oligodeoxyonucleotides.
aODN Sequences
Anti-Giα1 5′-G*C*T GTC CTT CCA CAG TCT CTT TAT GAC GCC G*G*C-3′
Anti-Giα2 5′-A*T*G GTC AGC CCA GAG CCT CCG GAT GAC GCC C*G*A-3′
Anti-Giα3 5′-G*C*C ATC TCG CCA TAA ACG TTT AAT CAC GCC T*G*-3′
Anti-Goα1 5′-A*G*G CAG CTG CAT CTT CAT AGG TG*T*T-3′
Anti-Goα2 5′-G*A*G CCA CAG CTT CTG TGA AGG CA*C*T-3′
Anti-Gsα 5′-T*T*G TTG GCC TCA CGC* T*G-3′
mODN Sequences
Anti-Giα1 5′-G*C*T GTC CTT CAC CAG TCT TCT TAT GAC CGC G*G*C-3′
Anti-Giα2 5′-A*T*G TGC AGC CCA AGG CCT CCG GAT GAC CGC C*G*A-3′
Anti-Giα3 5′-G*C*C TAC TCG CCA ATA ACG TTT AAT ACC GCC T*G*C-3′
Anti-Goα1 5′-A*G*G ACG CTG CTA CTT CAT GAG TG*T*T-3′
Anti-Gοα2 5′-G*A*G CAC CAG CTT TCG TGA AGG AC*C*T-3′
Anti-Gsα 5′-T*T*G TGT GCC TAC CGC* T*G-3′
dODN Sequences
Anti-Gi 5′-N*N*N NNN NNN NNN NNN NNN NNN NNN NNN NNN N*N*N-3′
Anti-Go 5′-N*N*N NNN NNN NNN NNN NNN NNN NN*N *N-3′
Anti-Gs 5′-N*N*N NNN NNN NNN NNN* N*N-3′
N=G, C, A or T.
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Animals
Sexually mature male albino Swiss Webster mice (Morini, S. Polo
d'Enza, Italy) weighing 30–40 g were used. Three to four mice were
housed per cage. The animals were fed a standard laboratory dietFig. 1. Effects of aODNs, mODNs and dODNs against Giα1–3 and Goα1–2 on hyperalgesia indu
after pre-treatment with ODNs in presence of 1 μg/kg morphine. Vertical bars represent S.Eand water ad libitum and kept at 23±1 °C with a 12-h light/dark
cycle. All experiments were carried out in accordance with the Euro-
pean Community Council Directive of November 24 1986 for experi-
mental animal care. All efforts were made to minimize the number
of animals used and their suffering.
Habituation procedure
All the animals were previously habituated to the laboratory
according to Abbot (Abbott et al., 1986). Mice were handled on each
of the two days preceding the start of the experiments. Mice were
allowed to habituate to the testing room for 30 min before hot plate
session.
Drugs and antisense oligonucleotide
Morphine HCl, naloxone and yohimbine were purchased from
Sigma Chemicals (St Louis, MO, USA). Phosphodiester oligonucleotides
(ODNs) protected from terminal phosphorothioate double substitution
(capped ODNs) and degenerate ODN (dODNs) were purchased by Tib
Molbiol (Berlin, Germany); ODNs were vehiculated intracellularly by
an artificial cationic lipid (DOTAP, Sigma).
Intracerebroventicular administration
Antisense oligodeoxynucleotides (aODNs), mismatch sequence
ODN (mODN), 33-mer fully degenerated ODN (33dODN) and 25mer
fully degenerated ODN (25dODN) were injected in a 5-μl final volume
of artificial cationic lipid (DOTAP, Sigma). aODNs, mODNs and dODNsced by 1 μg/kg morphine administration—licking latencies were measured before and
.M. *=αb0.01 vs saline. Each value represents the mean±S.E.M. of at least 15 mice.
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(intracerebroventricular) injections were performed into the right and
left cerebral ventricle according to the method described by Haley and
McCormick (1957) injecting 2.5 μl in each side of the brain.
Antisense oligodeoxynucleotides
We have used aODNs against Giα1–3, Goα1–2 and Gsα proteins. The
sequences of the above ODNs and their characterization are described
in a previous paper (Galeotti et al., 2002) and base composition is
reported in Table 1. As previously established (Standifer et al., 1996;
Sanchez-Blazquez and Garzon, 1998; Galeotti et al., 2002), we used
the lowest effective aODN doses (25 μg) to ensure the selectivity of
the response in hot plate test. The aODNs, mODNs and dODNs were
supplied to mice by i.c.v. injection 18 and 24 h before the starting of
the test. Three base pairs in the antisense sequence were reversed
to obtain the mODN respectively for Giα, Gοα and Gsα proteins, as
reported in Table 1. 33mer dODN, 25mer dODN and 17mer dODN
were used as control respectively for anti-Giα, Goα and Gsα proteins.
Hot plate test
According to O'Callaghan (O'Callaghan and Holtzman, 1975) mice
were placed inside a stainless steel container, which was setFig. 2. Effects of aODNs,mODNs anddODNs against Gsα on thermal hyperalgesia—licking la-
tencies were measured before and after pre-treatment with ODNs in presence of 1 μg/kg
morphine or after twice daily morphine administration for seven days. Vertical bars repre-
sent S.E.M. *=Pb0.01 vs saline. Each value represents themean±S.E.M. of at least 15mice.thermostatically at 52.5±0.1 °C in a precision water-bath from KW
mechanical workshop (Siena, Italy). Here we have used lower tem-
perature in hot plate test (52 °C instead of 54 °C). As previously
shown, increased temperatures result in a decrease of the response
latencies (Tjølsen et al., 1991). Therefore, lower temperatures are
useful to reveal possible subtle alterations that may occur in basal
nociception. The licking latency was measured immediately prior
s.c. (subcutaneous) morphine (1 μg/kg) injection. Hot plate test
started 15 min after morphine administration and licking latencies
were measured at 15 min intervals for 45 min after starting time.
Mice i.c.v. pretreated with aODNs, mODNs and dODNs, were injected
with a single s.c. morphine dose (1 μg/kg) and submitted to hot plate
test 15 min after. Other different group received s.c. injection of saline
or morphine (10 mg/kg) twice daily for 7 days, supplied with aODNs,
mODNs and dODNs by i.c.v. injection at the 6th and 7th days and sub-
mitted to hot plate test 24 h after the end of treatments. The licking
latencies were measured at the same times as above. A 30 s cut-off
to prevent tissue damage was used. The endpoint for the licking re-
sponse was the first paw lick of the rear paw. Anti-nociception was
seen as increased latencies to the responses evaluated while in-
creased nociception was seen by shorter latencies. The analgesic
tests were performed in a blind fashion.
Rota-rod test and spontaneous activity meter
For both tests, animals were i.c.v. pretreated 18–24 h before the
tests with dODNs or aODNs. Up to 5 mice were tested simultaneously
on the apparatus, with a rod rotating speed of 16 rpm. The integrity of
motor coordination was assessed on the basis of the number of falls
from the rod in 30 s according to Vaught (Vaught et al., 1985).
Performance was measured before treatment and 15, 30 and 45 min
after the starting of the experiments. Locomotor activity was quanti-
fied using a type S Animex activity meter (LKB, Farad, Sweden) set to
maximum sensitivity. Five mice were placed on the meter. The instru-
ment transformed movements into digital signals. Activity counts
were made every 15 min for 45 min.
Receptor-G protein coupling assay
Mice used for these experimentswere sacrificed 15 min after 1 μg/kg
morphine administration at which timemaximum thermal hyperalgesic
effect was obtained in hot plate test (Galeotti et al., 2006). The animals
were anesthetized with CO2, cervically dislocated, decapitated and
the brain dissected, put immediately in liquid nitrogen and then
stored at −80 °C. Enriched synaptic membranes were prepared
from brain of mice treated with morphine as described by Gray and
Whittaker (Gray and Whittaker, 1962). Protein concentration was
determined according to Lowry (Lowry et al., 1951). The association
of G protein coupled receptors with G proteins was investigatedFig. 3. Lack of effect by saline, vehicle and aODNs against Gi/o or Gs proteins adminis-
tered to mice at 2 nM/mouse, on mouse spontaneous mobility evaluated in the
mouse rotarod test. Vertical lines represent S.E.M.
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(Wang et al., 2005). The specificity of the anti-Gα and anti-α2 AR
antibodies was determined by Western blotting using 100 μl of
mouse whole brain homogenate with or without antigen peptide
(25 μg) pre-adsorption for 30 min. The specificity of anti-μOR anti-
body was previously assayed (Bianchi et al., 2009).
Western blot analysis
Western blot was performed as previously described in detail (Pan
et al., 1995). In summary, immunoprecipitates (from 1 μg/μl protein
lysate) of Giα1, Giα2, Giα3, and Gοα protein from brain of morphine
and saline pretreated mice were solubilized in SDS buffer and sepa-
rated on polyacrylamide gels (1.5 mm). Proteins were transferred to
nitrocellulose (1.5 h at 190 mA) and the membranes were blocked
in PBS containing 3% BSA for 1 h before addition of anti-μOR or anti-
α2 AR antibody at 1:500 dilution. The blots were stripped andFig. 4. Downregulation of Gi/o proteins—a representative immunoblot is shown with β-tubu
cord from five independent experiments are reported at the right side. Values are expressed
nificance level in comparison with control value. Vertical lines represent S.E.M.reprobed with antibodies against various G proteins using the anti-
sera against Giα1, Giα2, Giα3, and Gοα protein as probes at 1:1000 dilu-
tion. The blotting was visualized using a chemiluminescence
detection system (Super Signal West Fento, Pierce Biotechnology
Inc., Rockford, IL, USA) and quantified with the Versa Doc 1000
Imaging System (Bio-Rad Laboratories, Hercules, CA, USA). Three in-
dependent experiments were done at the same protein concentration
for each experimental condition. Specific bands were quantitated by
densitometric scanning.Controls
The mice which underwent the hot plate test were submitted to
paw temperature measurement 24 h, 10 min and 1 min before test-
ing. The temperature was measured with an infrared thermometer
(Omega, Standford, GT).lin as loading control. The mean±S.E.M. of density values obtained in brain and spinal
as percentage of density obtained in saline treated mice; *=difference at αb0.01 sig-
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their brains were excised and cut coronally to check the visible path
of i.c.v. injection. Only data from mice in which the injection was cor-
rectly located within ventricles were considered.Statistical analysis
All experimental results are given as mean±S.E.M. Analysis of
variance followed by Fisher protected least significant difference
(PLSD) procedure for post-hoc comparisons was used to verify signif-
icance between two means. Data were analysed with the Statview
Software for the Macintosh (1992).Results
Role of G protein subunits in morphine induced thermal hyperalgesia
Morphine hyperalgesia induced by s.c. 1 μg/kg dose in the mouse
hot plate test was blocked by pre-treatment with aODNs against
Giα1–3 and Goα1 (Fig. 1). The probes anti-Goα2 did not significantly
modify the hyperalgesic response induced by 1 μg/Kg morphine
dose (Fig. 1). Antisense ODN pre-treatment against Gsα could reverse
the hyperalgesic effect induced 24 h after the end of chronic mor-
phine treatment whereas was ineffective in presence of acute low
morphine dose administration (Fig. 2).Fig. 5. G protein-receptor coupling in brain from mice treated with morphine—a repre-
sentative Western blot of the presence of μOR and α2 AR protein in immunoprecipi-
tates of i1–3 and o subunits of Gα protein in brain from mice treated with saline
(control) or morphine at 1 μg/kg is shown in (a). The blots stripped and reprobed
with antibodies against the above G proteins are shown for morphine treatment and
control (a). Band optical density for Gα protein subunits is represented in (b). Each
bar represents the mean density of each Gα subunit obtained from three independent
experiments and is expressed as percent of corresponding saline. Statistics were ap-
plied to the raw data prior to transformation to percent. Mean value of μOR and α2
AR density detected in immunoprecipitates of considered Gα subunits are represented
in (b). Single values were normalized to surrounding background and expressed as ar-
bitrary units. *=αb0.01 vs saline. Vertical lines represent S.E.M.
Fig. 5. (continued)Rota-rod test
No significant differences were observed in the number of falls at
different times between saline, vehicle, aODN, mODN and dODN
pretreated mice. Therefore, no motor disturbances were observed in
rotarod test. Data are shown only for aODN against G protein (Fig. 3).
ODN immunoblotting
Immunoblotting revealed a significant decrease of Giα1–3 ,Goα1–2 and
Gsα expression in brain and spinal cord from mice previously treated
with corresponding aODN 18 and 24 h before sacrifice, with respect to
mODN treated mice (Fig. 4). Immunoblot was reprobed for a non-
regulatory protein,β-tubulin, and no significant differencewas revealed
for this protein between samples from brain or spinal cord.
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acute low morphine dose administration
Under non-denaturing conditions, specific G proteins (Giα1–3 and
Go) together with their coupled receptors were immunoprecipitated
with selective anti-Gα antibodies from solubilized synaptic membranes
obtained from brain of the different treatment groups under basal and
morphine-stimulated conditions. In our experiments, μOR coupled to
Giα2, Giα3 and Goα protein in low (1 μg/kg) dose morphine-treated
mice. α2 AR coupling to both Giα1 and Giα3 could be detected after
acute 1 μg/Kg dose morphine administration (Fig. 5a). Densitometric
scanning of immunoprecipitated proteins is represented in Fig. 5b.
Effect of μOR and ARα2 antagonists in morphine induced hyperalgesia
Morphine hyperalgesia induced by s.c. 1 μg/kg dose in the mouse
hot plate test was completely prevented by i.c.v. pre-treatment with
selective μOR antagonist CTOP at 0.5 ng/kg or selective ARα2 antago-
nist yohimbine (0.4 ng/kg) (Fig. 6).
Controls
When untreated or aODN administered or previously submitted to
immobilization proceduremice underwent hot plate test, no significant
difference could be detected as respect to saline controls (Fig. 7).
The skin temperature of the paws remained unchanged after ad-
ministration of the different pre-treatments (data not shown).
Discussion
Opioids are generally thought to produce inhibitory responses
evoking analgesia through inhibition of adenylyl cyclase activation
of K+ channels or inhibition of Ca++ channels. In some neuronal
clonal cultures, induced Ca++ increase was observed from cell
grown in sparse culture in presence of micromolar opioid concentra-
tion (Jin et al., 1992). Direct excitatory effects of opioids have been
also described in sensory neurons in presence of morphine lowFig. 6. Effect of CTOP and yohimbine coadministration onmorphine induced hyperalgesic re-
sponse—licking latencies weremeasured before and after (15, 30 and 45min) s.c. morphine
administration (1 μg/kg) in presence or absence of i.c.v. CTOP or yohimbine coadministra-
tion. Each value represents the mean±S.E.M. of licking latencies. Vertical bars represent
S.E.M. *=αb0.01 vs saline. Each value represents the mean±S.E.M. of at least 15 mice.dose. Nanomolar concentrations of opioids prolonged the duration
whereas micromolar concentrations shortened the duration of action
potential in mouse dorsal root ganglion neurons (Shen and Crain,
1989). The idea that high affinity excitatory effects are distinct from
low affinity inhibitory ones was supported by the observation that
nanomolar concentrations of opioids enhance enkephalin release
from the guinea pig myenteric plexus via cholera toxin sensitive pro-
cess whereas higher concentrations (10–100 nM) inhibited release by
a pertussis toxin sensitive pathway. It is well known that treatment
with pertussis toxin uncouples inhibitory receptors linked to the reg-
ulatory Gi and Go proteins whereas cholera toxin interferes with li-
gand activation of Gs linked excitatory receptors. Crain and Shen
(1998) showed, in primary dorsal root ganglion cultures, that neuro-
nal stimulation at nanomolar concentrations of opioids was coupled
with opioid receptor stimulatory Gs protein. In our experiments,
when groups of mice pretreated with 1 μg/kg morphine in presence
of aODNs targeting Giα1–3, Goα1–2 were submitted to acute thermal
nociceptive test, the downregulation of the Giα1–3, Goα1 proteins re-
versed the decreased licking latency responses induced by 1 μg/kg
morphine administration toward the basal licking latency value
whereas downregulation of Gsα protein was ineffective to reverse
the hyperalgesic effect. When mice were submitted to repeated
twice daily morphine administration, the downregulation of Gsα pro-
tein could reverse the hyperalgesic effect induced by the interruption
of morphine treatment. Although Gsα protein appears to be implicat-
ed in hyperalgesia induced in morphine abstinent mice, our data sup-
port that this condition is not realized in acute morphine treatment,
providing evidence that low dose morphine hyperalgesic effects are
supported by a separate molecular mechanism. Our results establish
that Gi proteins can play a role in the transduction mechanism re-
sponsible for the hyperalgesic effect produced in Swiss Webster
mice by low morphine dose. Previously, co-expression study in
transfected cells (Chan et al., 1995) indicated that opioid receptors
can induce excitatory effects by Gi protein activation of type II
adenylyl cyclase which appeared to be expressed primarily in the
brain (Feinstein et al., 1991); DAMGO induced stimulation of type II
adenylyl cyclase was increased in cells co-expressing either Giα1–3
and Goα1–2 proteins. Therefore, an excitatory system might be activated
also through Gi.
No hyperalgesic effect was induced by low dose morphine admin-
istration in completely untreated mice excluding that stress condition
associated with experimental procedure injections might induce a
analgesic effect counteracting the hyperalgesic effect induced by
low morphine doses.
The hyperalgesic effect obtained in presence of a lowmorphine dose
could be reverted in presence of selective μOR antagonist CTOP whereas
δOR and κOR antagonists were ineffective. Interestingly, the morphine
induced acute hyperalgesic effect could be reversed in presence of se-
lective α2 AR antagonist yohimbine. In co-immunoprecipitation
experiments, a pronounced coupling of μOR and α2 AR to α subunits
of Gi/o emerged in brain from mice systemically administered with
low morphine dose. These results suggest that both the descending
opioid and noradrenergic system appear as important components in
spinal/supraspinal interactive mechanisms that may mediate the
hyperalgesic action induced by low morphine dose. Although α2 ARs
do not seem involved in the opioid withdrawal-induced hyperalgesia
(Bie et al., 2003), our data show that these receptors are implicated
in morphine hyperalgesia through G inhibitory proteins.
Opioids such as morphine remain the most efficacious and widely
used analgesics for moderate to severe pain. Accumulating evidence
suggests that the administration of opioid analgesics might lead not
only to analgesia but also to a paradoxical sensitization to noxious
stimuli. Numerous clinical studies indicate that sustained opioid
treatment can also paradoxically cause hyperalgesia. A recent pro-
spective trial in which sustained-acting morphine was given to
patients with chronic low back pain demonstrated measurable
Fig. 7.Hot plate test in non-injected and aODN treatedmice—licking latenciesweremeasured before and after (15, 30 and45min) in untreated, restricted and aODN treatedmice in presence or
absence of naloxone. Each value represents themean±S.E.M. of licking latencies. Vertical bars represent S.E.M. *=Pb0.01 vs saline. Each value represents themean±S.E.M. of at least 15mice.
924 E. Bianchi et al. / Life Sciences 89 (2011) 918–925hyperalgesia within one month of beginning therapy (Chu et al.,
2006). Other human data suggest that hyperalgesia and allodynia
have been observed in human volunteers after opioid analgesia
(Guignard et al., 2000). The conventional practice of opioid therapy
in presence of diminishing analgesic efficacy is based on a dose esca-
lation to restore analgesic effects. Otherwise, the present data add a
possible new mechanism for previously explained observations fur-
ther corroborating the assumption that opioid induced hyperalgesia
can presently considered to be a physiological antagonist to analgesia.
These considerations offer a novel approach for the development of
strategies that could improve the use of opioids for pain.
Conclusions
In summary, our data showed that both opioid and adrenergic
systems are implicated in morphine induced excitatory effect through
G inhibitory protein activation.
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